Cargando…
Immune checkpoint signaling and cancer immunotherapy
Immune checkpoint blockade therapy has become a major weapon in fighting cancer. Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such as broad applicability across cancer types and durable clinical response when treatment is effective. However, the overall response r...
Autores principales: | He, Xing, Xu, Chenqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395714/ https://www.ncbi.nlm.nih.gov/pubmed/32467592 http://dx.doi.org/10.1038/s41422-020-0343-4 |
Ejemplares similares
-
Immune checkpoints and immunotherapy for colorectal cancer
por: Singh, Preet Paul, et al.
Publicado: (2015) -
Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy
por: Chikuma, Shunsuke, et al.
Publicado: (2017) -
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020) -
Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018) -
Immune checkpoints, their control by immunotherapy and ovarian cancer
por: Bose, Chinmoy K.
Publicado: (2017)